^
    Back
    Association details:
    Biomarker:ALK C1156Y
    Cancer:Non Small Cell Lung Cancer
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    ScienceDirect
    Title:

    Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment

    Excerpt:
    genomic DNA analysis from thirteen relapsed patients revealed three known crizotinib resistance mutations, C1156Y, L1196M and G1269A.
    DOI:
    10.1016/j.ygeno.2013.02.006
    Evidence Level:
    Resistant: C4 – Case Studies
    New
    Source:
    N Engl J Med
    Title:

    Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F

    Excerpt:
    The fraction of tumor cells harboring ALK C1156Y was less than 7% in the pretreatment tumor, approximately 50% in the crizotinib-resistant tumor, and approximately 100% in the lorlatinib-resistant tumor.
    DOI:
    10.1056/NEJMoa1508887